Welcome to our dedicated page for Synlogic news (Ticker: SYBX), a resource for investors and traders seeking the latest updates and insights on Synlogic stock.
Synlogic, Inc. news has centered on financial results and corporate updates for a biopharmaceutical company that developed genetically engineered probiotic drug candidates. Synlogic designed, developed, and manufactured drug candidates using precision genetic engineering applied to well-characterized probiotics, including GI-restricted orally administered biopharmaceuticals.
Recurring updates have covered the discontinuation of Synpheny-3, the pivotal study of labafenogene marselecobac (SYNB1934) in phenylketonuria, strategic-review activity, a limited-duration stockholder rights plan, Roche collaboration revenue, restructuring charges, and published data for SYNB1353 in classical homocystinuria.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Synlogic, Inc. (SYBX) announced its fourth-quarter and full-year 2022 financial results, highlighting significant advancements in its pipeline for treating phenylketonuria (PKU) and homocystinuria (HCU). The company is on track to initiate its pivotal Phase 3 trial for SYNB1934 in PKU by mid-2023. Additionally, it received Rare Pediatric Disease Designation for SYNB1934 and SYNB1353. Financially, Synlogic reported revenues of $1.2 million for 2022, a decrease from $1.8 million in 2021, with a net loss of $66.1 million, or $0.92 per share. The company has $77.6 million in cash to support operations through the second half of 2024.